FDA panel recommends easing restrictions on several peptides, including BPC-157
A narrow panel vote could let compounders make the peptides after FDA reviewers warned the evidence on safety and benefits remains limited.
- On Thursday, FDA advisers narrowly recommended adding four unapproved peptides—BPC-157, KPV, TB-500, and MOTS-C—to the "503A Bulks List," endorsing lifting restrictions that prevented compounding pharmacies from using them.
- Safety concerns led the FDA to ban these substances three years ago, but they have since surged in popularity among supporters of the "MAHA" agenda, with Health Secretary Robert F. Kennedy Jr. personally advocating for wider access.
- "There's stuff happening out there that we need to try and control," said panelist Haleem Mohammed, Chief Medical Officer of Gameday Men, as dissenters raised concerns about unknown risks and potential conflicts of interest.
- Agency reviewers previously advised against broader use, citing scant evidence regarding safety and efficacy, though the FDA usually follows advisory committee recommendations despite this narrow, divided vote.
- The panel debates three additional peptides—Emideltide, Semax, and Epitalon—on Friday, testing the agency's willingness to expand the "503A Bulks List" despite reviewers' warnings about unknown safety profiles.
115 Articles
115 Articles
FDA Panel Backs Wider Access to Six Peptide Therapies, Citing Grey Market Concerns › American Greatness
A Food and Drug Administration (FDA) advisory panel has voted to recommend expanding legal access to six popular peptide compounds. Supporters say could pull patients […] Source
Health advisors met on Thursday to review more than half a dozen unproven peptides, substances that have become a growing trend of well-being, despite little evidence that they are safe or effective.
A federal advisory panel voted to increase access to a popular peptide. Here's what that means. - The Mexico Ledger
A federal advisory panel has voted to increase access to a popular peptide. Here's what that means.A federal advisory committee has recommended making BPC-157, a peptide popular in online wellness and fitness circles, available again through licensed compounding pharmacies.The FDA’s Pharmacy Compounding Advisory Committee voted to recommend adding BPC-157 to the 503A Bulks List, the set of substances that compounding pharmacies may prepare for p…
Coverage Details
Bias Distribution
- 57% of the sources are Center
![[your]NEWS](/_next/image?url=https%3A%2F%2Fgroundnews.b-cdn.net%2Finterests%2Ffb6dc495f74049f513563c33352175eaa0ecd509.jpg%3Fwidth%3D60&w=128&q=75)
Factuality
To view factuality data please Upgrade to Premium
